Related Experiment Video
Updated: Apr 20, 2026
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
Molecular Heterogeneity of Triple Negative Breast Cancer
Vandana G Abramson1, Ingrid A Mayer1
1Department of Medicine; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center; Vanderbilt University School of Medicine, Nashville, TN.
Abstract:
Triple-negative breast cancers (TNBCs) are known to be an aggressive group of breast cancers with higher rates of relapse stage for stage compared to ER/PR positive and HER2 positive breast cancers despite optimal loco-regional and systemic therapies. To date, not a single targeted therapy has been approved for the treatment of TNBC, and cytotoxic chemotherapy remains the standard systemic treatment. Recently, gene expression analyses identified six distinct TNBC subtypes, each displaying a unique biology. In this review we will discuss current and upcoming therapeutic strategies exploring novel approaches to targeted treatment of these TNBC subtypes.
Insights
Triple-negative breast cancer (TNBC) is aggressive and lacks targeted therapies. Gene expression reveals six subtypes, guiding novel treatment strategies for better outcomes.
Area of Science:
- Oncology
- Genomics
- Translational Medicine
Background:
- Triple-negative breast cancer (TNBC) exhibits aggressive behavior and high relapse rates compared to other breast cancer subtypes.
- Current standard treatment for TNBC relies on cytotoxic chemotherapy, with no approved targeted therapies available.
- Recent advancements in gene expression profiling have identified six distinct TNBC subtypes with unique biological characteristics.
Purpose of the Study:
- To review current and emerging therapeutic strategies for triple-negative breast cancer.
- To explore novel approaches for targeted treatment based on identified TNBC subtypes.
- To provide an overview of the therapeutic landscape for aggressive breast cancer subtypes.
Main Methods:
- Literature review of current and upcoming therapeutic strategies for TNBC.
- Analysis of gene expression data to identify distinct TNBC subtypes.
- Discussion of targeted treatment approaches tailored to TNBC subtype biology.
Main Results:
- TNBC is a heterogeneous disease with at least six distinct molecular subtypes.
- Each TNBC subtype possesses unique biological drivers and potential therapeutic vulnerabilities.
- Novel targeted therapies are being developed to address the specific biology of these subtypes.
Conclusions:
- Targeted therapies hold promise for improving outcomes in specific TNBC subtypes.
- Understanding TNBC heterogeneity is crucial for developing effective personalized treatment strategies.
- Future research should focus on subtype-specific therapeutic interventions for TNBC.
